By creator to www.biospace.com
SUWON, Republic of Korea, April 17, 2020 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a key participant within the improvement of RNAi therapeutics, at present introduced the appointment of Dr. Gordon Jiang, Dr. Aaron Hakim and Dr. Yury V. Popov to its Scientific Advisory Board (SAB). The SAB will work with OliX Prescription drugs government workforce to refine the rising pipeline in addition to medical technique for the corporate’s belongings.
“We’re happy to welcome Dr. Jiang, Dr. Hakim and Dr. Popov, famend liver illness consultants, to OliX Prescription drugs’ Scientific Advisory Board,” stated Dong-Ki Lee, Ph.D., founder and Chief Govt Officer of OliX Prescription drugs. “Their depth of scientific experience will probably be vital as we enter a pivotal section in advancing the Firm’s liver fibrosis pipeline.”
Backgrounds of Newly Appointed Scientific Advisory Board Members
- Yury V. Popov, MD, PhD, is the founding father of the Popov Laboratory and an assistant professor of drugs at Beth Israel Deaconess Medical Middle (BIDMC) and Harvard Medical College. Dr. Popov’s lab focuses on liver fibrosis/cirrhosis and its life-threatening sequelae. He leads the investigation of primary mechanisms of development and regression of liver scarring. Popov’s laboratory can be actively engaged on the event, validation and optimization of small animal fashions of cirrhosis and liver most cancers for novel drug goal discovery and efficacy testing. Dr. Popov is an affiliate editor of the American journal of Physiology-Gastrointestinal and Liver Physiology and editorial board member for over 30 scientific journals together with Hepatology, Gastroenterology, Journal of Medical Investigation and Science Translational Drugs. Dr. Popov obtained an MD from Grodno Medical College, Belarus and PhD in biochemistry from the Institute of Biochemistry of Nationwide Academy of Sciences of Belarus.
- Aaron Hakim, MD, is a resident doctor in inner drugs at BIDMC and a medical fellow at Harvard Medical College. Dr. Hakim served as a vp at Nice Level Companions, a biotechnology-focused funding fund. His analysis has appeared in peer reviewed journals together with the Journal of Hepatology, The Journal of the American Medical Affiliation and the Journal of Organic Chemistry. Dr. Hakim earned his medical diploma with honors at Yale College of Drugs and graduated summa cum laude from Yale College with an M.S. in Molecular Biology and a B.S. in Economics and Molecular Biology.
- Gordon Jiang, MD, is a transplant hepatologist and physician-scientist at BIDMC. He’s the affiliate director of the Doctor-Scientist program at BIDMC that helps careers of clinicians dedicated to medical translations and primary science investigation. He has over 20 years of analysis expertise in lipid metabolism and fatty liver illnesses, primarily specializing in each alcoholic and non-alcoholic fatty liver illnesses. His present analysis focuses on ldl cholesterol toxicity, liver irritation and liver fibrosis. Dr. Jiang is a recipient of trade awards from the American Affiliation for the Examine of Liver Ailments, the American School of Gastroenterology and Gilead Sciences.
OliX Prescription drugs
OliX Prescription drugs is a medical stage pharmaceutical firm growing therapeutics towards a wide range of problems by down-regulating expression of disease-causing genes, primarily based by itself proprietary RNAi expertise. The Firm’s core RNAi platform, uneven siRNA (asiRNA), is a novel gene silencing expertise primarily based on RNA interference (RNAi), which is taken into account as essentially the most environment friendly gene silencing expertise. Primarily based on asiRNA expertise, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to successfully goal regionally administrable illnesses, equivalent to hypertrophic scar, dry and moist age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic ache. OliX has additionally developed one other therapeutic RNAi platform, GalNAc-asiRNA, to focus on a wide range of liver illnesses.
— to www.biospace.com